Agenus (NASDAQ:AGEN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Agenus (NASDAQ:AGEN) from a strong-buy rating to a hold rating in a research report sent to investors on Monday.

Other equities research analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $25.00 price target (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a research report on Thursday, July 30th. Zacks Research cut Agenus from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.50.

Agenus Price Performance

Shares of Agenus stock opened at $8.26 on Monday. The firm has a 50 day simple moving average of $5.11 and a 200 day simple moving average of $4.04. The firm has a market cap of $371.87 million, a P/E ratio of 3.20 and a beta of 1.41. Agenus has a fifty-two week low of $2.71 and a fifty-two week high of $8.85.

Agenus (NASDAQ:AGEN) last released its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The business had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. On average, sell-side analysts expect that Agenus will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AGEN. EP Wealth Advisors LLC acquired a new position in Agenus during the fourth quarter valued at approximately $31,000. R Squared Ltd bought a new position in shares of Agenus in the 4th quarter valued at $41,000. Redwood Family Wealth LLC acquired a new stake in shares of Agenus during the fourth quarter valued at about $44,000. Quadrature Capital Ltd acquired a new stake in Agenus during the 4th quarter worth approximately $54,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Agenus in the third quarter worth $54,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.